investor southern California The California Institute for Regenerative Medicine (CIRM) elected Jonathan Thomas to be its next president. Thomas will succeed Robert Klein, the real estate investor that led to the desire to create the public agency funded and led to his first 6 years. CIRM board faces a decision between Thomas and Frank Litvack, a cardiologist and medical device entrepreneur. According to the California Stem Cell Report blog, the vote was 14 to 11.
In his remarks before the vote of the Board, Thomas stressed his experience in finance as an essential qualification for the position.
With California in an unspecified financial crisis, CIRM may have to find sources of funding other than government bonds that have enabled it to provide to date $ 1.25 billion in grants and loans for research on stem cells, Thomas said. Thomas noted that it was a major premed biology at Yale University before turning to finance, and said he had always hoped to return to biology if the right opportunity arose. "This is an opportunity," he said.
0 Komentar